Low frequency of TEL-AML1 in relapsed acute lymphoblastic leukemia supports a favorable prognosis for this genetic subgroup

Leukemia

Volumn 13, Issue 1, 1999, Pages 19-21

  Rubnitz, J E ^a,b   Behm, F G ^a,b   Wichlan, D ^a   Ryan, C ^a   Sandlund, J T ^a,b   Ribeiro, R C ^a,b   Rivera, G K ^a,b   Hancock, M L ^a   Relling, M V ^a,b   Evans, W E ^a,b   Pui, C H ^a,b   Downing, J R ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

Leukemia; Relapse; TEL AML1

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; FEMALE; FOLLOW UP; FUSION GENE; GENE EXPRESSION; HUMAN; MALE; PRIORITY JOURNAL; PROGNOSIS; RELAPSE;

EID: 0032921624     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401257     Document Type: Article

References (18)

1. Pui C-H, Evans WE. Acute lymphoblastic leukemia. New Engl J Med 1998; 339: 605-614.
2. Shurtleff SA, Buijs A, Behm FG, Rubnitz JE, Raimondi SC, Hancock ML, Chan GC, Pui CH, Grosveld G, Downing JR. TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia 1995; 9: 1985-1989.
3. Rubnitz JE, Behm FG, Pui C-H, Evans WE, Relling MV, Raimondi SC, Harrison PL, Sandlund JT, Ribeiro RC, Grosveld G, Downing JR. Genetic studies of childhood acute lymphoblastic leukemia with emphasis on p76, MLL, and ETV6 gene abnormalities: results of St Jude Total therapy Study XII. Leukemia 1997; 11: 1201-1206.
4. Rubnitz JE, Shuster JJ, Land VJ, Link MP, Pullen DJ, Camitta BM, Pui C-H, Downing JR, Behm FG. Case-control study suggests a favorable impact of TEL rearrangement in patients with B-lineage acute lymphoblastic leukemia treated with antimetabolite-based therapy: a Pediatric Oncology Group study. Blood 1997; 89: 1143-1146.
5. Rubnitz JE, Downing JR, Pui C-H, Shurtleff SA, Raimondi SC, Evans WE, Head DR, Crist WM, Rivera GK, Hancock ML, Boyett JM, Buijs A, Grosveld G, Behm FG. TEL gene rearrangement in acute lymphoblastic leukemia: a new genetic marker with prognostic significance. J Clin Oncol 1997; 15: 1150-1157.
6. Borkhardt A, Cazzaniga G, Viehmann S, Valsecchi MG, Ludwig WD, Burci L, Mangioni S, Schrappe M, Riehm H, Lampert F, Basso G, Masera G, Harbott J, Biondi A. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Blood 1997; 90: 571-577.
7. McLean TW, Ringold S, Neuberg D, Stegmaier K, Tantravahi R, Ritz J, Koeffler HP, Takeuchi S, Janssen JWG, Seriu T, Bartram CR, Sallan SE, Gilliland DG, Golub TR. TEL/AML1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood 1996; 88: 4252-4258.
8. Seeger K, Adams HP, Buchwald D, Beyermann B, Kremens B, Niemeyer C, Ritter J, Schwabe D, Harms D, Schrappe M, Henze G. TEL-AML1 fusion transcript in relapsed childhood acute lymphoblastic leukemia. The Berlin-Frankfurt-Munster Study Group. Blood 1998; 91: 1716-1722.
9. Harbott J, Viehrnann S, Borkhardt A, Henze G, Lampert F. Incidence of TEL/AML1 fusion gene analyzed consecutively in children with acute lymphoblastic leukemia in relapse. Blood 1997; 90: 4933-4937.
10. Rivera GK, Raimondi SC, Hancock ML, Behm FG, Pui CH, Abromowitch M, Mirro J Jr, Ochs JS, Look AT, Williams DL et al. Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy. Lancet 1991; 337: 61-66.
11. Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. New Engl J Med 1998; 338: 499-505.
12. Pui CH, Relling MV, Behm FG, Hancock ML, Boyett JM, Raimondi SC, Krance RA, Mahmoud HH, Ribeiro RC, Sandlund JT et al. t-asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins. Leukemia 1995; 9: 1680-1684.
13. Prentice RL, Kalbfleisch JD, Peterson AVJ, Flournoy N, Farewell VT, Breslow NE. The analysis of failure times in the presence of competing risks. Biometrics 1978; 34: 541-554.
14. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141-1154.
15. Takahashi Y, Horihe K, Kiyoi H, Miyashita Y, Fukuda M, Mori H, Nozaki C, Hasegawa S, Kawabe T, Kato K, Kojima S, Matuyama T, Naoe T. Prognostic significance of TEL/AML1 fusion transcript in childhood B-precursor acute lymphoblastic leukemia. J Pediatr Hematol Oncol 1998; 20: 190-195.
16. Nakao M, Yokota S, Horiike S, Taniwaki M, Kashima K, Sonoda Y, Koizumi S, Takaue Y, Matsushita T, Fujimoto T, Misawa S. Detection and quantification of TEL/AML1 fusion transcripts by polymerase chain reaction in childhood acute lymphoblastic leukemia. Leukemia 1996; 10: 1463-1470.
17. Cayuela JM, Baruchel A, Orange C, Madani A, Auclerc MF, Daniel MT, Schaison G, Sigaux F. TEL-AML1 fusion RNA as a new target to detect minimal residual disease in pediatric B-cell precursor acute lymphoblastic leukemia. Blood 1996; 88: 302-308.
18. Zuna J, Hrusak O, Kalinova M, Huzikova K, Stary J, Trka J. TEL/AML1 positivity in childhood ALL: average or better prognosis? Leukemia 1999; 13: 22-24.